Canadian Cancer Trials Group Bulletins


Recent Publication

The final results of Canadian Cancer Trials Group MY.10 - A Randomized Phase III Study of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma - were recently published online in Blood.

The authors reported that maintenance therapy with thalidomide-prednisone following autologous stem cell transplant improves the duration of disease control, but is associated with worsening of patient-reported HRQoL and no detectable overall survival benefit.

Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Rubinger M, Cantin G, Song K, Tompkins KA, Marcellus DC, Lacy MQ, Sussman J, Reece D, Brundage M, Harnett EL, Shepherd L, Chapman JA, Meyer RM. A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) with a quality of life assessment: Canadian Cancer Trials Group MY.10 Trial (ONLINE). Blood 2013.